title: Saxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adults.
abstract: Type 2 diabetes affects millions of people worldwide and significantly contributes to morbidity and mortality of those affected by it. Current guidelines recommend individualized treatment regimens following first line metformin therapy. Saxagliptin, a dipeptidyl-peptidase 4 inhibitor, provides a secondary mechanism of action to decrease hyperglycemia when used in combination with metformin. The combination of metformin and saxagliptin has shown improvements in hemoglobin A1c and fasting plasma glucose in greater efficacy than when either agent is used alone. Adverse effects of combination therapy are similar to when these agents are used individually, and are rated as tolerable by patient satisfaction scores. Overall, the combination use of saxagliptin in addition to metformin is an attractive option for clinicians to use in the treatment of type 2 diabetes.
authors: School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas.
authors: Molly G
authors: MG
authors: Minze
authors: Mary S
authors: MS
authors: Klein
authors: Brian T
authors: BT
authors: Terrell
keywords: metformin; saxagliptin; type 2 diabetes combination therapy
references: Diabetes Metab Syndr Obes. 2010 May 10;3:117-24
references: 21437082
references: Lancet. 2011 Jul 9;378(9786):182-97
references: 21705062
references: Diabetes Care. 2009 Sep;32(9):1649-55
references: 19478198
references: Diabetes. 2002 Jul;51(7):2074-81
references: 12086935
references: Gastroenterology. 2007 May;132(6):2131-57
references: 17498508
references: Clin Med Insights Endocrinol Diabetes. 2011;4:1-12
references: 22879789
references: J Intern Med. 2012 Jul;272(1):1-12
references: 22321169
references: Diabetol Metab Syndr. 2013 Feb 15;5(1):6
references: 23415113
references: Clin Drug Investig. 2012 Mar 1;32(3):189-202
references: 22292415
references: Diabetes Res Clin Pract. 2011 Nov;94(2):217-24
references: 21871686
references: Diabetes Obes Metab. 2011 Jul;13(7):604-14
references: 21332626
references: Am J Med. 2010 Mar;123(3 Suppl):S38-48
references: 20206731
references: Diabetes Obes Metab. 2012 Oct;14 Suppl 3:152-60
references: 22928576
references: Diabetes Care. 2012 Jan;35 Suppl 1:S64-71
references: 22187472
references: Diabetes Obes Metab. 2012 Apr;14(4):365-71
references: 22192246
references: J Clin Invest. 2001 Oct;108(8):1167-74
references: 11602624
references: Endocr Rev. 2007 Apr;28(2):187-218
references: 17353295
references: Eur J Intern Med. 2013 Jan;24(1):20-6
references: 23177353
references: Diabetes Care. 2011 May;34 Suppl 2:S276-8
references: 21525468
references: J Biol Chem. 2004 Nov 12;279(46):47898-905
references: 15371448
references: Diabetes Care. 2001 Mar;24(3):489-94
references: 11289473
references: Rev Assoc Med Bras (1992). 2012 May-Jun;58(3):294-301
references: 22735220
references: Clin Pharmacol Ther. 2010 Dec;88(6):801-8
references: 21048706
references: Diabetes Metab Syndr Obes. 2011;4:263-71
references: 21792325
references: N Engl J Med. 2012 Apr 5;366(14):1319-27
references: 22475595
references: Clin Drug Investig. 2011;31(9):619-30
references: 21819160
references: Postgrad Med. 2011 Jul;123(4):63-70
references: 21680990
references: Diabetes Care. 2012 Jun;35(6):1364-79
references: 22517736
references: Int J Clin Pract. 2010 Nov;64(12):1619-31
references: 20846286
references: Int J Clin Pract. 2011 Mar;65(3):314-22
references: 21314869
references: Diabetes Obes Metab. 2012 Jan;14 Suppl 1:20-9
references: 22118707
references: Diabetes. 2000 Dec;49(12):2063-9
references: 11118008
references: Diabetes Obes Metab. 2009 Jun;11(6):611-22
references: 19515181
references: N Engl J Med. 2008 Oct 9;359(15):1577-89
references: 18784090
references: Am J Med Sci. 2012 Jan;343(1):13-6
references: 22205060
references: Am J Med. 2009 Jun;122(6 Suppl):S3-S10
references: 19464426
references: Diabetes Obes Metab. 2011 Jun;13(6):567-76
references: 21342412